In this podcast, 3 members of the Cancer.Net Editorial Board discuss new research presented at the 2023 ASCO Annual Meeting in non-small cell lung cancer, small cell lung cancer, and mesothelioma.
2023 ASCO Annual Meeting Research Round Up: Progress in Preventing Melanoma Recurrence and Improving Equity in Cancer Care
In this podcast, 2 Cancer.Net Associate Editors discuss new research presented at the 2023 ASCO Annual Meeting about preventing melanoma recurrence and reducing cancer disparities.
2023 ASCO Annual Meeting Research Round Up: Progress in Treating Breast Cancer, Lymphoma, Multiple Myeloma, and Brain Tumors
In this podcast, 3 Cancer.Net Associate Editors discuss new research presented at the 2023 ASCO Annual Meeting in breast cancer, lymphoma, multiple myeloma, brain tumors, and von Hippel-Lindau syndrome.
In this post, melanoma survivor Bryant Wieneke reflects on what it was like being diagnosed with advanced disease, how he felt more vulnerable after being diagnosed with a second cancer years later, and how he is supporting his mental health.
ASCO Annual Meeting 2023: Trastuzumab Deruxtecan Effectively Treats HER2-Expressing Tumors and CAR T-cell Therapy Helps Slow or Stop Multiple Myeloma
The ASCO Annual Meeting is being held June 2 to 6. Research highlights from the day include using trastuzumab deruxtecan to treat HER2-expressing tumors and using CAR T-cell therapy to slow or stop multiple myeloma.
ASCO Annual Meeting 2023: Improving Outcomes in Glioma, Hodgkin Lymphoma, Lung Cancer, Ovarian Cancer, and Rectal Cancer
The ASCO Annual Meeting is being held June 2 to 6. Several notable studies will be presented today. Topics include radiation therapy in rectal cancer, osimertinib for lung cancer, vorasidenib for grade 2 glioma, nivolumab for Hodgkin lymphoma, and mirvetuximab soravtansine for ovarian cancer.
ASCO Annual Meeting 2023: Adding Durvalumab and Olaparib to Treatment Delays Growth of Ovarian Cancer
The ASCO Annual Meeting is being held June 2 to 6. A study that will be presented today explores combining immunotherapy and targeted therapy to reduce the risk of death and recurrence for people with advanced ovarian cancer.
The ASCO Annual Meeting is being held June 2 to 6, and here is some of the notable research that will be presented today. Topics include treatment for anemia related to myelodysplastic syndromes, pembrolizumab for advanced cervical cancer, surgery options for early pancreatic cancer, weight loss in breast cancer survivorship, the effect of Medicare expansion on racial disparities, and collaborating across borders to help children with leukemia.
Tumors With KRAS G12C Mutation Respond to Adagrasib and Using Toripalimab to Treat Stage III Lung Cancer: The ASCO Plenary Series
Read about 2 studies from the April 2023 ASCO Plenary Series, which highlights the use of adagrasib to target several solid tumors with a KRAS G12C mutation and the use of toripalimab to treat stage III non-small cell lung cancer before and after surgery.
New Research in Treating Non-Hodgkin Lymphoma and Predicting the Risk of Early Disease Progression: ASH Annual Meeting 2022
In this podcast, Dr. Christopher Flowers discusses new research from the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition, including new treatments for non-Hodgkin lymphoma and models for predicting early disease progression.